Induction of multinucleation in oral squamous cell carcinoma tissue with mutated p53 surviving boron neutron capture therapy

Fujita, Yasuhisa; Yamamoto, Naofumi; Kato, Ikunoshin; Iwai, Shinichi; Ono, Koji; Sakurai, Yoshinori; Ohnishi, Ken; Ohnishi, Takeo; Yura, Yoshiaki

doi:10.3109/09553002.2011.530336

Cited by 5 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If DNA damage is not repaired, cell cycle arrest and different mechanisms of cell death could be activated. Apoptosis, necrosis, autophagy, or mitotic catastrophe has been described in different cell lines and in vivo models after BNCT [ 47 , 94 , 95 , 96 ]. In this sense, the development of boron compounds that could target DNA and/or the cell nucleus is in the spotlight.…”

Section: Development Of New Boron Carriersmentioning

confidence: 99%

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies

Hughes

2023

Cancers

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed, in this review, those articles published between 2020 and 2023 reporting new boron compounds and strategies that were proved therapeutically useful in in vitro and/or in vivo radiobiological studies, a critical step for translation to a clinical setting. We also explored new pathologies that could potentially be treated with BNCT and newly developed theranostic boron agents. All these radiobiological advances intend to solve those limitations and questions that arise during patient treatment in the clinical field, with BNCT and other therapies. In this sense, active communication between clinicians, radiobiologists, and all disciplines will improve BNCT for cancer patients, in a cost- and time-effective way.

show abstract

Section: Development Of New Boron Carriersmentioning

confidence: 99%

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies

Hughes

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Instead, HR is associated with the late S and G2 phase (Refs44, 107). If DNA damage is not repaired, DNA damage-induced signalling pathways are activated and elicit cell cycle arrest and/or apoptosis, necrosis, autophagy or mitotic catastrophe (Refs110, 114, 115).…”

Section: Radiobiological Mechanisms Induced By Bnctmentioning

confidence: 99%

Importance of radiobiological studies for the advancement of boron neutron capture therapy (BNCT)

Hughes

2022

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a tumour selective particle radiotherapy, based on the administration of boron carriers incorporated preferentially by tumour cells, followed by irradiation with a thermal or epithermal neutron beam. BNCT clinical results to date show therapeutic efficacy, associated with an improvement in patient quality of life and prolonged survival. Translational research in adequate experimental models is necessary to optimise BNCT for different pathologies. This review recapitulates some examples of BNCT radiobiological studies for different pathologies and clinical scenarios, strategies to optimise boron targeting, enhance BNCT therapeutic effect and minimise radiotoxicity. It also describes the radiobiological mechanisms induced by BNCT, and the importance of the detection of biomarkers to monitor and predict the therapeutic efficacy and toxicity of BNCT alone or combined with other strategies. Besides, there is a brief comment on the introduction of accelerator-based neutron sources in BNCT. These sources would expand the clinical BNCT services to more patients, and would help to make BNCT a standard treatment modality for various types of cancer. Radiobiological BNCT studies have been of utmost importance to make progress in BNCT, being essential to design novel, safe and effective clinical BNCT protocols.

show abstract

“…Fujita et al showed that oral SCC with mutated TP53 recurred after BNCT, while oral SCC with wild‐type TP53 was completely cured by BNCT using an animal model. Masunaga et al reported a decrease in BPA uptake under hypoxic conditions in TP53 mutated SCC cells in vitro.…”

Section: Boron Neutron Capture Therapymentioning

confidence: 99%

Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients

Yura

Tada

Fujita

et al. 2019

Oral Science International

Self Cite

View full text Add to dashboard Cite

Malignant tumors such as squamous cell carcinoma (SCC), malignant salivary gland tumor, mucosal melanoma, sarcoma, and lymphoma occur in the oral cavity. Among them, oral SCC accounts for 90%. The frequency of lymph node metastasis of oral SCC varies depending on the site of occurrence, which affects the prognosis. Surgery is the primary treatment for oral cancer, but when the tumor extends, postoperative radiation with or without chemotherapy is required. Photons including X-rays and γ-rays are the most widely used types of ionizing radiation in cancer radiotherapy. Particle radiotherapy using protons and carbon ions shows a highly focused dose distribution to tumor tissues. Carbon ion therapy is effective for salivary gland tumors, malignant melanomas, and sarcomas which are less susceptible to photons. Furthermore, boron neutron capture therapy with tumor selectivity is expected to further reduce damage to surrounding normal cells. The introduction of novel radiotherapy to current treatment might improve the prognosis of patients and organ preservation. K E Y W O R D S chemotherapy, oral cancer, particle radiotherapy, radiotherapy, surgery How to cite this article: Yura Y, Tada S, Fujita Y, Hamada M. Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients. Oral Sci Int. 2019;16:49-68. https://doi.

show abstract

Induction of multinucleation in oral squamous cell carcinoma tissue with mutated p53 surviving boron neutron capture therapy

Cited by 5 publications

References 34 publications

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies

Importance of radiobiological studies for the advancement of boron neutron capture therapy (BNCT)

Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients

Contact Info

Product

Resources

About